
The Chemours Company (NYSE:CC – Free Report) – Equities research analysts at Zacks Research cut their FY2026 earnings estimates for shares of Chemours in a research report issued to clients and investors on Monday, November 16th. Zacks Research analyst Team now anticipates that the specialty chemicals company will post earnings per share of $0.73 for the year, down from their prior forecast of $0.83. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Chemours’ Q4 2026 earnings at $0.05 EPS, Q3 2027 earnings at $0.51 EPS, Q4 2027 earnings at $0.52 EPS, Q1 2028 earnings at $0.44 EPS, Q2 2028 earnings at $0.59 EPS and Q3 2028 earnings at $0.42 EPS.
Chemours (NYSE:CC – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.05). Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the previous year, the business earned $0.40 EPS. The company’s quarterly revenue was up 3.0% on a year-over-year basis.
Read Our Latest Stock Analysis on CC
Chemours Price Performance
Shares of NYSE:CC opened at $12.06 on Tuesday. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -11.83 and a beta of 1.47. The firm has a fifty day moving average price of $13.57 and a 200 day moving average price of $18.11. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The company has a debt-to-equity ratio of 24.25, a quick ratio of 0.98 and a current ratio of 1.81.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of CC. Deutsche Bank AG purchased a new stake in shares of Chemours during the 2nd quarter valued at about $3,291,000. The Manufacturers Life Insurance Company bought a new position in shares of Chemours in the 2nd quarter valued at about $1,522,000. BlackRock Inc. bought a new position in shares of Chemours in the 2nd quarter valued at about $477,769,000. Jefferies Financial Group Inc. bought a new position in shares of Chemours in the 2nd quarter valued at about $15,996,000. Finally, Old West Investment Management LLC purchased a new position in Chemours in the second quarter worth about $7,152,000. 76.26% of the stock is owned by hedge funds and other institutional investors.
Chemours Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be given a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Monday, November 16th. Chemours’s dividend payout ratio is currently -34.31%.
Latest Chemours News
Here’s some of the latest news about CC:
- Neutral Sentiment: General Counsel Kristine Wellman plans to retire, and Amy Rocklin has been appointed as her successor, effective January 4, 2027. The announcement does not indicate a change in business strategy. Chemours general counsel succession announcement
- Negative Sentiment: Multiple law firms publicized a securities class action against Chemours and certain executives, alleging investors were misled about demand for Opteon refrigerants during February 20–August 4, 2026. The allegations are not proven, but the litigation adds legal and reputational risk; investors have until December 7 to seek lead-plaintiff status. Chemours securities class action announcement
- Negative Sentiment: Zacks Research cut its EPS estimates across several periods, including FY2027 to $1.71 from $2.05 and FY2028 to $1.98 from $2.31, and maintained a “Strong Sell” rating. The weaker profit outlook may weigh on sentiment.
About Chemours
The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.
Featured Articles
- Five stocks we like better than Chemours
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.
